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OBJECTIVES We sought to determine the clinical factors and heritability associated with inflammation
measured as circulating levels of soluble-intercellular adhesion molecule-1 (sICAM-1) in a
community-based cohort.
BACKGROUND Several prospective studies indicate that circulating sICAM-1 is predictive of future
cardiovascular events. However, in some studies this predictive value is lost after multivariable
adjustment for traditional cardiovascular disease (CVD) risk factors. We addressed the
heritability of sICAM-1 and its relation to CVD risk factors in a community-based cohort.
METHODS We examined 3,295 subjects from the Framingham Heart Study and measured sICAM-1
levels. We then used linear and stepwise multivariable regression to determine predictors or
sICAM-1 levels.
RESULTS In age- and gender-adjusted regression models, increased sICAM-1 levels were positively
associated with age, total/high-density lipoprotein cholesterol, systolic blood pressure, body
mass index (BMI), blood glucose, diabetes, smoking, and prevalent CVD. In stepwise
multivariable regression models, sICAM-1 levels remained associated with age, female
gender, total/high-density lipoprotein cholesterol ratio, BMI, blood glucose, smoking, and
prevalent CVD. The residual heritability of sICAM-1 was 24%.
CONCLUSIONS In addition to prevalent CVD, established CVD risk factors and non-traditional ones such as
BMI were associated with systemic inflammation as determined by sICAM-1 levels. There
also is significant heritability of sICAM-1, which suggests a genetic component to systemic
inflammation. (J Am Coll Cardiol 2004;44:168–73) © 2004 by the American College of
Cardiology Foundationm
p
c
l
c
T
c
c
M
S
F
(
i
2
R
w
r
p
i
u
(
c
mhe notion that inflammation plays a role in the develop-
ent of clinical manifestations of atherosclerosis now is
rmly established (1). The recruitment of inflammatory
ells into the arterial wall is dependent upon cellular
dhesion molecules and begins with leukocyte rolling on the
ndothelium that is facilitated by endothelial expression of
-selectin and its interaction with leukocyte P-selectin
lycoprotein ligand-1 (2). Firm leukocyte adhesion requires
n interaction between leukocyte beta1 and beta2 integrins
nd endothelial adhesion molecules such as vascular cell
dhesion molecule-1 and intracellular adhesion molecule-1,
espectively (3). With respect to the latter, several prospec-
ive studies have demonstrated that circulating soluble levels
f intracellular adhesion molecule-1 (sICAM-1) are predic-
ive of future cardiovascular events (4–6) and the develop-
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rom the NIH.
Manuscript received December 4, 2003; revised manuscript received February 10,(004, accepted March 16, 2004.ent of peripheral arterial disease (7). The independent
redictive value of sICAM-1 with respect to incident
ardiovascular disease (CVD) is controversial because it is
ost after multivariable adjustment for traditional cardiovas-
ular risk factors in some studies (6) but not others (4,5,7).
o address this issue, we examined the heritability and
ross-sectional correlates of serum sICAM-1 levels in a
ommunity-based cohort.
ETHODS
tudy sample. The design and selection criteria of the
ramingham Offspring study have been described elsewhere
8). The current sample was derived from the 3,539 partic-
pants attending the seventh examination cycle (1998 to
001), and all procedures were approved by the Institutional
eview Board of Boston Medical Center. Attendees under-
ent a routine physical examination, medical history, labo-
atory assessment of cardiovascular risk factors, and anthro-
ometric measurements. The clinical definition of diabetes
ncluded fasting glucose 126 mg/dl, oral hypoglycemic
se, or insulin use. Information about prior CVD events
coronary heart disease [CHD], stroke, intermittent claudi-
ation, congestive heart failure [CHF]) was obtained by
edical histories, physical examinations at the Heart Studyevery 4 years), and hospitalization and personal physician
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July 7, 2004:168–73 Correlates of sICAM in the Communityecords. The latter were reviewed by a panel of three
xperienced investigators using previously described criteria
9). Subjects were excluded if they underwent physical
xamination off-site (n  205), if serum was unavailable (n
30), or if covariate data were missing (n  9), which left
,295 subjects for the current investigation.
etermination of sICAM-1. Serum samples were col-
ected and stored at 70°C. For analysis, samples were
hawed at room temperature, vortexed vigorously, and the
ICAM-1 determined using a commercially available
nzyme-linked immunosorbent assay (R & D Systems,
inneapolis, Minnesota) according to the manufacturer’s
nstructions and expressed as ng/ml. Samples were analyzed
n duplicate with an average intra-assay coefficient of vari-
tion of 3.7  2.4%. All samples with a coefficient of
ariation greater than two standard deviations from this
ean (8.8%) were repeated in duplicate, and the mean of
he repeat duplicate values was used in this analysis.
tatistical analysis. Ninety-nine percent of the sICAM-1
alues were within the range of 29 to 550 ng/ml, and the
istribution was approximately normal in this range. Ap-
roximately 1% of sICAM-1 values were between 543
g/ml and the maximum of 1,332 ng/ml. The distribution
f sICAM-1 was asymmetric, but analyses performed on
aw (untransformed) and log-transformed data were virtu-
lly identical. We present untransformed data because they
re more easily understood clinically.
Age- and gender-adjusted linear regression models were
onstructed to assess relations of sICAM-1 to the following
ndividual variables: total/high-density lipoprotein (HDL)
holesterol, systolic blood pressure (BP), diastolic BP, body
ass index (BMI), waist-to-hip ratio, fasting glucose level,
istory of diabetes, smoking, hypertension treatment, and
istory of myocardial infarction (MI), CHF, or CVD.
ender and age interactions also were tested for each
ariable listed above. Stepwise linear regression multivari-
ble models (10) were constructed with sICAM-1 against
he above variables with a p  0.10 threshold for inclusion.
he Framingham CHD Risk Score was calculated as
escribed previously (11) except age was not included,
ecause we age-adjusted sICAM-1 levels in analyses using
he risk score. In addition, adjusted logistic regression
odels were constructed with prevalent CVD as the out-
ome to assess its relation with sICAM-1 (12). Analyses
Abbreviations and Acronyms
BMI  body mass index
BP  blood pressure
CHD  coronary heart disease
CHF  congestive heart failure
CVD  cardiovascular disease
MI  myocardial infarction
sICAM-1  soluble intracellular adhesion molecule-1ere run using SAS version 8.1 (Cary, North Carolina) (13). Any two-sided p value less than 0.05 was considered to
e statistically significant.
We used Sequential Oligogenic Linkage Analysis Rou-
ines (14) to estimate residual heritability of sICAM-1, that
s, the proportion of variability attributable to genetic effects
fter accounting for measured covariates. The underlying
odel assumed that trait variation could be partitioned into
enetic and environmental (measured covariate) factors.
he genetic component was assumed to be polygenic
ithout dominance components. We estimated residual
eritability after accounting for gender and age and then
fter accounting for multiple additional covariates. The
ortion of variation resulting from measured covariates was
etermined using a regression model with men and women
ombined.
ESULTS
ubject characteristics and individual predictors of
ICAM-1. Characteristics of the study sample are dis-
layed in Table 1. As expected, CVD was more prevalent in
en (18%) than women (9%). Because men and women
xhibited similar serum levels of sICAM-1 and because
ach covariate effect on sICAM-1 was similar for men and
omen, gender-pooled analyses were performed. Age- and
ender-adjusted regression was conducted using variables
rom Table 1 as correlates of sICAM-1 (Table 2). Advanc-
ng age positively correlated with sICAM-1, as was total/
DL cholesterol ratio, systolic BP, diabetes, history of
ypertension treatment, smoking, MI, and CVD. Serum
lucose also was positively associated with sICAM-1. Obe-
ity, measured as overall adiposity (BMI) or its pattern
able 1. Baseline Characteristics of the Study Sample
Men
(n  1,535)
Women
(n  1,760)
ge, yrs (range) 61  10 (37–89) 61  9 (33–87)
otal cholesterol, mg/dl 192  35 207  37
otal/HDL cholesterol 4.5  1.4 3.7  1.2
ystolic blood pressure,
mm Hg
128  17 126  20
iastolic blood pressure,
mm Hg
76  10 72  10
asting glucose mg/dl 109  29 101  25
ody mass index, kg/m2 28.8  4.6 27.6  5.8
aist-to-hip ratio 1.0  0.1 0.9  0.1
iabetes 17% 11%
moking 13% 13%
istory of CVD 18% 9%
istory of MI 8% 2%
istory of CHF 2% 1%
ypertension treatment 37% 31%
ipid-lowering
treatment
25% 17%
ICAM-1 (ng/ml) 259  81 258  85
ll numbers are mean  SD (continuous), or percent (categorical).
CHF  congestive heart failure; CVD  cardiovascular disease; HDL 
igh-density lipoprotein; MI  myocardial infarction; sICAM-1  soluble intercel-
ular adhesion molecule-1.waist-to-hip ratio), also emerged as a strong positive
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Correlates of sICAM in the Community July 7, 2004:168–73orrelate of sICAM-1, but we found no significant associ-
tions between sICAM-1 and either heart failure (p 0.20)
r diastolic BP (p  0.66).
ultivariable correlates of sICAM-1 levels. The results
f age- and gender-adjusted stepwise multivariable linear
egression models are shown in Table 3. Age remained a
ighly significant correlate of sICAM-1, and gender
merged as a significant correlate in the multivariable
odel, with women averaging sICAM-1 levels that were 9
g/ml higher than men. The emergence of gender as a
redictor of sICAM-1 was driven by the entrance of
otal/HDL cholesterol ratio in the model because women
ad higher average sICAM-1 levels than men at any given
evel of total/HDL cholesterol ratio. Other strong positive
redictors of sICAM-1 were smoking and total/HDL
holesterol ratio. Smokers demonstrated an adjusted mean
ICAM-1 that was 25% higher than non-smokers (309 
00 ng/ml vs. 251  78 ng/ml, respectively). Fasting
able 2. Age- and Gender-Adjusted Regression Models for
erum sICAM-1 Levels
Regression
Coefficients p Value
ge, 10 yrs 8.02 0.0001
ender, female vs. male 0.0073 0.99
otal/HDL cholesterol, 2 U 16.27 0.0001
ystolic blood pressure,
20 mm Hg
4.09 0.014
iastolic blood pressure,
10 mm Hg
0.67 0.66
ody mass index, 5 kg/m2 7.40 0.0001
aist-to-hip ratio, 0.075 10.08 0.0001
lood glucose, 25 mg/dl 9.82 0.0001
iabetes, present 26.01 0.0001
moking, present 63.38 0.0001
ypertension treatment, present 8.30 0.010
istory of CHF, present 16.36 0.20
istory of MI, present 18.02 0.009
istory of CVD, present 22.89 0.0001
ll linear regression coefficients represent the estimated change in sICAM-1 (ng/ml)
er specified number of units (continuous, approximately 1 SD) or presence
dichotomous) of the variable. Each covariate was analyzed separately, adjusting for
ge and gender. Two-tailed p values were obtained for T coefficient/(standard error
f coefficient) using the t distribution.
Abbreviations as in Table 1.
Table 3. Multivariable Correlates of sICAM-1
Variable, U
Regression
(95%
Age, 10 yrs 9.35 (6.35
Gender, female vs. male 8.75 (2.97
Smoking, present 61.93 (53.7
Blood glucose, 25 mg/dl 6.04 (3.36
Total/HDL cholesterol 10.06 (5.60
History of CVD, present 15.88 (7.43
Body mass index, 5 kg/m2 5.15 (2.07
Regression coefficients represent the estimated change in sI
variable. All covariates were analyzed simultaneously, select
section. Two-tailed p values were obtained for T  coeffic
confidence intervals (CIs) were obtained using coefficient 
the above seven variables is 10.2%. The partial R2 (%) is the r
the full model. Note that the sum of the partial R2 does noAbbreviations as in Table 1.lucose also was associated with increased sICAM-1 levels
ecause each 25-mg/dl increase in fasting glucose was
ssociated with a 6-ng/ml adjusted mean increase in
ICAM-1. Although some previous studies have suggested
hat sICAM-1 is merely a reflection of CVD risk factors, we
ound that prevalent CVD was highly associated with
ICAM-1 levels (Table 3) and that this relation was not
elated to time from CVD diagnosis (p  0.70 for time
ffect).
To examine the relation between established CHD risk
nd sICAM-1, we plotted age-adjusted mean sICAM-1 (
ne standard error) by gender-specific Framingham CHD
isk score (11) quintile for men and women without prev-
lent CVD (Fig. 1). We found that increasing quintiles of
isk scores were associated with increasing levels of
ICAM-1. To determine whether sICAM-1 adds signifi-
antly to the risk factor profile of CVD beyond traditional
isk factors, we performed multivariable logistic regression
ith prevalent CVD as the outcome variable and found that
els
cient
p Value
Partial R2
(%)
5) 0.0001 1.0
3) 0.0030 0.24
.08) 0.0001 6.06
) 0.0001 0.54
2) 0.0001 0.53
3) 0.0002 0.37
) 0.0002 0.37
-1 (ng/ml) per specified number of units (1 SD) of the
a stepwise method as described in the Statistical Analysis
standard error of coefficient) using the t distribution; 95%
standard error of coefficient). The R2 of the full model with
on in R2 that would occur if the variable were removed from
the model R2 of 10.2.
igure 1. Age-adjusted serum soluble intracellular adhesion molecule-1
sICAM-1) in relation to Framingham Risk Score for subjects without
revalent cardiovascular disease. Age-adjusted serum sICAM-1 levels are
lotted as a function of gender-specific quintile Framingham Risk Score for
oth men and women without prevalent cardiovascular disease. The
ender- and age-adjusted relation between risk score and sICAM-1 was
ignificant by multivariable linear regression (p  0.001).Lev
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July 7, 2004:168–73 Correlates of sICAM in the Communityirculating sICAM-1 levels remained a significant risk
actor (p  0.002) even after adjusting for the components
f the Framingham risk score. In fact, after adjusting for all
ariables in Table 1 (except history of MI and CHF),
ICAM-1 remained a significant risk factor for prevalent
VD (OR 1.10 for a 50-ng/ml increase in sICAM-1, 95%
onfidence interval of 1.03 to 1.17; p  0.004).
In addition to these variables, our data support a relation
etween obesity and sICAM-1. With respect to BMI, we
ound that each 5 kg/m2 increase was associated with a
-ng/ml increase in sICAM-1 levels (p  0.0002 after
djustment for variables in the stepwise model). To ensure
his relation was truly a reflection of obesity, we substituted
aist-to-hip ratio for BMI in the multivariable model and
e found it also was significantly associated with serum
ICAM-1 levels (p  0.004). To characterize the relation
etween obesity and this marker of inflammation, we
lotted mean sICAM-1 as a function of normal, over-
eight, and obese BMI levels in non-smokers and we
bserved a progressive relation between increasing BMI
ategory and sICAM-1 levels (Fig. 2).
With regard to the variability in sICAM-1 levels, the
nal multivariable model explained approximately 10.2% of
he variability (Table 3). Among variables in Table 1,
moking was the most important predictor of sICAM-1
evels and alone accounted for 6% of the variability (Table
). The heritability of sICAM-1 was estimated as 25.7 
.9% (estimate  standard error) adjusted for gender and
ge and as 24.3  6% after adjustment for multiple
ovariates (p  0.0001). Taking into account correlations
mong siblings in the multivariable model had no material
igure 2. Unadjusted serum soluble intracellular adhesion molecule-1
sICAM-1) in relation to body mass index (BMI) in non-smokers. Serum
ICAM-1 levels are plotted for non-smoking subjects grouped according to
ormal (18.5 to 24.9), overweight (25.0 to 29.9), or obese (30) BMI with
he number of observations (N) given in each group. The relationship
etween sICAM-1 levels and BMI did not vary significantly by gender or
moking status and was significant by gender- and age-adjusted multiva-
iable linear regression (p  0.001).mpact on the analyses listed in Table 3. wWe performed several secondary analyses to ensure that
ur results were not confounded by the presence of CVD or
edications. We found that excluding patients with CVD
ad no material effect on the results contained in Table 3.
imilarly, excluding patients on hypertension treatment or
n lipid-lowering medication had no material impact on the
esults.
ISCUSSION
onsiderable evidence now links both atherosclerosis and
oronary artery disease events to a state of vascular inflam-
ation (15). Consistent with this notion, we found that
levated levels of sICAM-1 were related to CVD risk
actors and prevalent CVD. We also found that sICAM-1
as related to CVD risk factors after excluding subjects with
revalent CVD, suggesting sICAM-1 is linked to early
therosclerosis. The notion that sICAM-1 may reflect
reclinical early atherosclerosis is not without precedent.
igands for ICAM-1 include the beta2 integrins CD11a/
D18 (LFA-1) and CD11b/CD18 (Mac-1), which are
resent on inflammatory cells such as neutrophils, mono-
ytes, and lymphocytes. Atherosclerotic lesions of all stages
emonstrate expression of ICAM-1 (16), and mice deficient
n either CD18 or ICAM-1 are resistant to diet-induced
therosclerosis (17). Moreover, in vivo studies in apoli-
oprotein E-deficient mice (18) and humans (19,20) sug-
est that sICAM-1 levels parallel the extent of atheroscle-
osis. Therefore, available data indicate that the
evelopment of atherosclerosis is, in part, dependent upon
CAM-1.
In addition to the morphologic development of athero-
clerosis, clinical studies suggest a relation between
CAM-1 and CVD events. For example, prospective case-
ontrol studies have linked elevated sICAM-1 levels to
ncident CHD (4–6,21) and peripheral vascular disease (7).
ith respect to the former, this relationship was lost after
ultivariable adjustment for traditional cardiovascular risk
actors in some studies (6,21), suggesting that sICAM-1
evels are simply a “barometer” for established risk factors.
ndeed, Rohde et al. (22) determined sICAM-1 levels in
48 participants of the Physician’s Health Study and found
ignificant independent associations with smoking, diabetes,
ystolic BP, and a positive family history of coronary disease.
ith respect to CVD risk factors, our data agree with that
f Rohde et al. in that age, smoking, and diabetes were all
ositively associated with sICAM-1 levels (Table 3). In
ontrast, this study does not support the notion that
ICAM-1 is simply a reflection of CVD risk factors because
e did find an association between prevalent CVD and
ICAM-1 levels that was independent of traditional CVD
isk factors and the Framingham Risk Score.
The data presented here demonstrate an association
etween indices of obesity and sICAM-1 levels, after
djusting for other CVD risk factors, which is consistent
ith a connection between obesity and inflammation. In-
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Correlates of sICAM in the Community July 7, 2004:168–73eed, several studies have found that C-reactive protein, a
ystemic marker of inflammation, is positively associated
ith BMI (23–25). Smaller studies have suggested that
dhesion molecules (26) are associated with obesity and
mprove with weight loss (27). Although the precise mech-
nism whereby obesity is linked to inflammation remains
nclear, adipose tissue is now recognized as a source of
roinflammatory cytokines such as tumor necrosis factor-
lpha (28) and interleukin-6 (29). Given that circulating
evels of C-reactive protein are readily elevated in response
o interleukin-6 (30,31), it is plausible that adipose secretion
f inflammatory cytokines could lead to increased circulat-
ng levels of C-reactive protein. A similar phenomenon may
xplain the relation of adiposity to sICAM-1 because
uman endothelial cells in culture release ICAM-1 in
esponse to cytokines such as tumor necrosis factor-alpha
nd interleukin-1 (32).
It is intriguing that both obesity and prevalent CVD are
ssociated with inflammation, because the link between
besity and CVD has been contentious. Past studies found
hat the independent effect of obesity on CVD was modest,
eading to conclusions that it was of limited significance
33–35). More recent investigation indicates that obesity
as a profound impact on other CVD risk factors and, thus,
hould be considered an independent hazard for CVD. For
xample, clusters of more than two CVD risk factors are
ore common in obese subjects (BMI30) than in subjects
ot overweight or obese (BMI 25) (36), and weight
eduction is associated with a concomitant reduction in
lobal risk factor sum (37). In light of the data presented
ere on sICAM-1 and obesity, it is attractive to speculate
ne component of any link between obesity and other CVD
isk factors is the promotion of systemic inflammation.
lthough the contribution of obesity to sICAM-1 was
odest, such speculation fits well with emerging evidence
hat inflammation may be a cause, rather than a conse-
uence, of active atherosclerosis. Indeed, the injection of a
eriodontal pathogen in apolipoprotein E-heterozygous
ice enhances the development of atherosclerosis (38) and
he inflammatory marker C-reactive protein itself induces
ndothelial cell activation (39) and endothelial dysfunction
40). Taken together, these data support speculation that
besity may partially contribute to the clinical manifesta-
ions of atherosclerosis through the promotion of a height-
ned inflammatory state.
To our knowledge, this is the first report of the herita-
ility of sICAM-1, which we found to be 24%. This level of
eritability is comparable with the heritability of left ven-
ricular mass (41). There is increasing interest in the
elationship between genetic variation in inflammatory
arkers and the risk of clinical and subclinical CVD (42).
olymorphisms in sICAM-1 have been related to diabetes
43), CHD, and MI (44). However, the genetic basis of
ascular inflammation and the relation between genetic
olymorphisms in inflammatory genes and CVD are in-
ompletely understood. Our finding that vascular inflam-ation is modestly heritable would suggest that its genetic
asis merits further investigation.
There are several limitations of the present study that
arrant consideration. First and foremost, we used
ICAM-1 as an index of inflammation. Although plasma
evels of soluble adhesion molecules are thought to originate
rom vascular cells through proteolytic cleavage and shed-
ing (32), the precise source of sICAM-1 and factors that
nfluence its clearance from plasma remain unknown.
herefore, our results could merely represent some change
n the clearance of sICAM-1 rather than a reflection of its
roduction per se. Additionally, because the sample was
erived from a single measurement in ambulatory volun-
eers, sICAM-1 levels may have been confounded by
edication status. We investigated such potential con-
ounding by separately analyzing people not receiving lipid-
owering or hypertension medications and noted consistency
n findings with those observed in the entire sample. Finally,
he Framingham cohort is not ethnically diverse, and the
xtent to which our findings are applicable to other ethnic
roups is not known at this time.
In summary, the data presented here support an associ-
tion between circulating sICAM-1 levels and prevalent
VD as well as with established CVD risk factors such as
ge, smoking, increasing glucose levels, and total/HDL
holesterol ratio. Circulating levels of sICAM-1 were also
odestly related to obesity, suggesting one mechanism
hereby obesity may contribute to the clinical manifesta-
ions of CVD. Finally, we found modest heritability of
ICAM-1 levels, suggesting that investigation into the
enetic determinants of inflammation is likely to be fruitful.
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